RxDoctor Payments Data

Rogelio Suarez, MD

Psychiatry · South Miami, FLNPI 1932514965

Payments from drug & device makers

$16,361in general payments, 2019–2025

Across 657 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Johnson & Johnson$2K
  • Alkermes, Inc.$1K
  • plus $5K from 19 others

What the payments were for

  • Food & beverage$16,26999%
  • Education$931%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,361 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$85,358
Medicare patients
188
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole19$27,558
VraylarCariprazine Hcl11$14,400
BelsomraSuvorexant13$5,713
ViibrydVilazodone Hcl12$4,090
Bupropion XlBupropion Hcl94$2,913
Mirtazapine78$2,107
Quetiapine Fumarate82$2,102
Clonazepam174$1,884
Venlafaxine Hcl ErVenlafaxine Hcl48$1,184
Quetiapine Fumarate ErQuetiapine Fumarate18$1,059
Duloxetine Hcl22$1,011
Trazodone Hcl148$847
Escitalopram Oxalate111$808
Sertraline Hcl141$754
Memantine Hcl32$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$2,181$27,55819 claims
AbbVieVraylar, Viibryd$2,939$18,49023 claims
MerckBelsomra$27$5,71313 claims
Almatica Pharma LLCSertraline Hcl$143$754141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →